{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:10:03Z","timestamp":1789431003746,"version":"build-2803163510"},"reference-count":83,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tim Ibbotson and Jeanne McKeon of Lumanity, Communications Inc."},{"name":"Kedrion Biopharma Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Intravenous (IV) iron is used to replenish iron stores in patients with iron-deficiency anemia (IDA) who do not benefit from oral iron supplementation. Hypophosphatemia is an increasingly recognized adverse event associated with certain IV iron formulations. Mild\/moderate hypophosphatemia may be asymptomatic or present with symptoms similar to those seen in patients with IDA, including fatigue, malaise, and muscle weakness. Persistent hypophosphatemia can cause osteomalacia due to reduced bone mineralization, leading to bone pain and pseudofractures. Ferric carboxymaltose (FCM) can impact phosphate homeostasis through an increase in fibroblast growth factor 23, leading to increased urinary phosphate excretion and hypophosphatemia. In clinical trials, rates of hypophosphatemia were significantly higher in patients receiving FCM compared with other IV iron formulations, such as ferric derisomaltose and ferumoxytol. Treatment guidelines recommend monitoring serum phosphate levels in patients receiving FCM who are at risk for low phosphate or who require repeat infusions, and alternative iron formulations should be considered in at-risk patients. This narrative review summarizes current evidence regarding IV iron-induced hypophosphatemia in individuals with IDA and examines the underlying pathophysiology and clinical evidence for IV iron-induced hypophosphatemia, particularly with FCM, the populations most at risk, and the clinical consequences of persistent hypophosphatemia.<\/jats:p>","DOI":"10.3390\/jcm15124748","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:04:04Z","timestamp":1781874244000},"page":"4748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hypophosphatemia in Patients Receiving Intravenous Iron Supplementation for Iron-Deficiency Anemia: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3502-1357","authenticated-orcid":false,"given":"Giovanni","family":"Inghilleri","sequence":"first","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Fatebenefratelli Sacco, 20157 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-0580","authenticated-orcid":false,"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13045-021-01202-2","article-title":"Burden of anemia and its underlying causes in 204 countries and territories, 1990\u20132019: Results from the Global Burden of Disease Study 2019","volume":"14","author":"Safiri","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/S2352-3026(23)00160-6","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990\u20132021: Findings from the Global Burden of Disease Study 2021","volume":"10","author":"Gardner","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","article-title":"Iron deficiency","volume":"397","author":"Pasricha","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ajh.27710","article-title":"Hypoferremic response to chronic inflammation is controlled via the hemojuvelin\/hepcidin\/ferroportin axis and does not involve hepcidin-independent regulation of Fpn mRNA","volume":"100","author":"Liu","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_5","first-page":"85","article-title":"Coronation in iron biology\u2014Hemojuvelin takes the throne?","volume":"57","year":"2026","journal-title":"Acta Haematol. Pol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, L., Liang, D., Huangfu, H., Shi, X., Liu, S., Zhong, P., Luo, Z., Ke, C., and Lai, Y. (2024). Iron deficiency: Global trends and projections from 1990 to 2050. Nutrients, 16.","DOI":"10.3390\/nu16203434"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41591-025-03624-8","article-title":"Global, regional and national burden of dietary iron deficiency from 1990 to 2021: A Global Burden of Disease study","volume":"31","author":"Lee","year":"2025","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2023.8020","article-title":"Prevalence of iron deficiency and iron-deficiency anemia in US females aged 12\u201321 years, 2003\u20132020","volume":"329","author":"Weyand","year":"2023","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/ejh.12776","article-title":"Epidemiology of iron deficiency anaemia in four European countries: A population-based study in primary care","volume":"97","author":"Levi","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cgh.2024.03.046","article-title":"AGA clinical practice update on management of iron deficiency anemia: Expert review","volume":"22","author":"DeLoughery","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","article-title":"British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults","volume":"70","author":"Snook","year":"2021","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","article-title":"Recent and emerging therapies for iron deficiency in anemia of CKD: A review","volume":"79","author":"Bazeley","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"IV1","DOI":"10.1136\/gut.46.suppl_4.iv1","article-title":"Guidelines for the management of iron deficiency anaemia","volume":"46","author":"Goddard","year":"2000","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: A review of their chemistry and key safety aspects\u2014Hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ajh.27598","article-title":"Ferric carboxymaltose (FCM)-associated hypophosphatemia (HPP): A systematic review","volume":"100","author":"Magagnoli","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Steinheiser","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eprac.2022.07.005","article-title":"Hypophosphatemia: A practical guide to evaluation and management","volume":"28","author":"Tebben","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1885","DOI":"10.1210\/clinem\/dgae633","article-title":"Serum phosphate in the general population: A need for sex-specific reference intervals","volume":"110","author":"Bosman","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","article-title":"High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: A benefit-risk assessment","volume":"45","author":"Boots","year":"2022","journal-title":"Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5049\/EBP.2010.8.2.72","article-title":"Fluid and electrolyte disturbances in critically ill patients","volume":"8","author":"Lee","year":"2010","journal-title":"Electrolytes Blood Press."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jfma.2024.06.010","article-title":"Unveiling the heightened susceptibility: Exploring early hypophosphatemia in critically ill trauma patients","volume":"124","author":"Yang","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1365-2044.1998.00463.x","article-title":"Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit","volume":"53","author":"Bugg","year":"1998","journal-title":"Anaesthesia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ziaf010","DOI":"10.1093\/jbmrpl\/ziaf010","article-title":"Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone","volume":"9","author":"Hidaka","year":"2025","journal-title":"JBMR Plus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","article-title":"Modern iron replacement therapy: Clinical and pathophysiological insights","volume":"107","author":"Girelli","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: Systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/vox.12773","article-title":"Canadian expert consensus: Management of hypersensitivity reactions to intravenous iron in adults","volume":"114","author":"Lim","year":"2019","journal-title":"Vox Sang."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100543","DOI":"10.1016\/j.jacig.2025.100543","article-title":"Intravenous iron reactions: Insights from an allergy and immunology perspective","volume":"4","author":"Jaggers","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_29","first-page":"5531805","article-title":"Extravasation of intravenous iron: Clinical features and therapeutic considerations","volume":"2026","author":"Tazegul","year":"2026","journal-title":"Case Rep. Hematol."},{"key":"ref_30","first-page":"e75323","article-title":"Addressing venous extravasation, a concern in intravenous iron administration","volume":"16","author":"Almeida","year":"2024","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20543581231165705","DOI":"10.1177\/20543581231165705","article-title":"Skin staining following intravenous iron extravasation in a patient with chronic kidney disease: A case report","volume":"10","author":"Shi","year":"2023","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ndt\/gfad188","article-title":"The basics of phosphate metabolism","volume":"39","author":"Wagner","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.26100","article-title":"Parenteral iron therapy and phosphorus homeostasis: A review","volume":"96","author":"Ganz","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_34","first-page":"569","article-title":"Clinical disorders of phosphorus metabolism","volume":"147","author":"Yu","year":"1987","journal-title":"West J. Med."},{"key":"ref_35","first-page":"370","article-title":"When physiology meets the built environment: The phosphorus story","volume":"135","year":"2025","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1210\/en.2004-0233","article-title":"Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders","volume":"145","author":"Bai","year":"2004","journal-title":"Endocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/sj.ki.5001813","article-title":"Proximal tubular handling of phosphate: A molecular perspective","volume":"70","author":"Forster","year":"2006","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14740\/jh2111","article-title":"Iron-induced hypophosphatemia: A review of pathophysiology, drug safety, and pharmacogenomic perspectives","volume":"14","author":"Pozzessere","year":"2025","journal-title":"J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): A randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose","volume":"107","author":"Schaefer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11136-024-03642-y","article-title":"Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease","volume":"33","author":"Bjorner","year":"2024","journal-title":"Qual. Life Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Emrich, I.E., Lizzi, F., Siegel, J.D., Seiler-Mussler, S., Ukena, C., Kaddu-Mulindwa, D., D\u2019Amelio, R., Wagenpfeil, S., Brandenburg, V.M., and B\u00f6hm, M. (2020). Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study. BMC Med., 18.","DOI":"10.1186\/s12916-020-01643-5"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11684-023-1001-2","article-title":"A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China","volume":"18","author":"Jin","year":"2024","journal-title":"Front. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(20)31539-7","article-title":"Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): A randomised, double-blind, controlled trial","volume":"396","author":"Richards","year":"2020","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e253093","DOI":"10.1001\/jamanetworkopen.2025.3093","article-title":"Intravenous iron-induced hypophosphatemia in surgical patients","volume":"8","author":"Richards","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ygh2.415","article-title":"Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose\u2014Real world experience from a tertiary centre in the UK","volume":"2","author":"Fragkos","year":"2020","journal-title":"GastroHep"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"468675","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int. J. Rheumatol."},{"key":"ref_61","first-page":"4017","article-title":"Intravenous iron related hypophosphatemia and potential preventing role of vitamin D supplementation: \u201creal life\u201d data from an outpatient clinic in north Italy","volume":"9","author":"Inghilleri","year":"2025","journal-title":"HemaSphere"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: A systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a complication of intravenous iron infusion: A systematic review of case reports","volume":"37","author":"Vilaca","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"115559","DOI":"10.1016\/j.bone.2020.115559","article-title":"Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency","volume":"141","author":"Frazier","year":"2020","journal-title":"Bone"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2023-174508","article-title":"Incidence of fractures after intravenous iron: A retrospective analysis comparing ferric carboxymaltose and ferric derisomaltose","volume":"142","author":"Zoller","year":"2023","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wagner, S.A., Panzer, M., Pertler, E., Redl, S., Saretto, M., Schaefer, B., Pammer, L.M., Obholzer, L., Troppmair, M.R., and Hess, M.W. (2026). Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia. Blood.","DOI":"10.1182\/blood.2025031806"},{"key":"ref_67","first-page":"005824","article-title":"Treatment-resistant hypophosphataemia after ferric carboxymaltose: Expanding the spectrum of 6H syndrome (hypophosphataemia, hyperphosphaturia, hypovitaminosis D, hypocalcaemia, secondary hyperparathyroidism, high fibroblast growth factor-23)","volume":"12","author":"Rashid","year":"2025","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_68","first-page":"467","article-title":"Life-threatening hypophosphatemia following intravenous iron infusion","volume":"41","author":"Chapel","year":"2021","journal-title":"Nefrol. (Engl. Ed.)"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Rosano, G., Ezekowitz, J., Nemeth, E., Ponikowski, P., Rauner, M., Seid, M., Spahn, D.R., Stein, J., Wish, J., and Mentz, R.J. (2025). Evaluating the risk of hypophosphatemia with ferric carboxymaltose and the recommended approaches for management: A consensus statement. J. Clin. Med., 14.","DOI":"10.3390\/jcm14144861"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Netzer, S., Buchel, L., Buchi, A.E., and Aubert, C.E. (2025). Indications for the evaluation and supplementation of hypophosphatemia: An umbrella systematic review of reviews and guidelines. BMC Med., 23.","DOI":"10.1186\/s12916-025-04415-1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"111727","DOI":"10.1016\/j.jclinane.2024.111727","article-title":"Ferric carboxymaltose with or without phosphate substitution in iron deficiency or iron deficiency anemia before elective surgery\u2014The DeFICIT trial","volume":"101","author":"Kaserer","year":"2025","journal-title":"J. Clin. Anesth."},{"key":"ref_72","unstructured":"(2026, March 10). Ferinject 50 mg iron\/mL Dispersion for Injection\/Infusion. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc\/print."},{"key":"ref_73","unstructured":"(2026, March 10). INJECTAFER\u00ae (Ferric Carboxymaltose Injection), for Intravenous Use. Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203565s009lbl.pdf."},{"key":"ref_74","unstructured":"Medicines and Healthcare Products Regulatory Agency (2026, March 10). Ferric Carboxymaltose (Ferinject): Risk of Symptomatic Hypophosphataemia Leading to Osteomalacia and Fractures, Available online: https:\/\/www.gov.uk\/drug-safety-update\/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures."},{"key":"ref_75","first-page":"ziae139","article-title":"In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution","volume":"8","author":"Grambeck","year":"2024","journal-title":"JBMR Plus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/hematology.2023000521","article-title":"Incidence, mechanism, and consequences of IV iron-induced hypophosphatemia","volume":"2023","author":"Martens","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_77","unstructured":"(2026, March 10). MONOFERRIC\u2014Ferric Derisomaltose Injection. Prescribing Information. Available online: https:\/\/www.monoferric.com\/."},{"key":"ref_78","unstructured":"(2026, March 10). Monofer 100 mg\/mL Solution for Injection\/Infusion. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/5676\/smpc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e70191","DOI":"10.1002\/nop2.70191","article-title":"Understanding and managing infusion reactions and hypophosphataemia with intravenous iron\u2014A nurses\u2019 consensus paper","volume":"12","author":"Fraser","year":"2025","journal-title":"Nurs. Open"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13696998.2025.2487359","article-title":"A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease","volume":"28","author":"Lindgren","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/13696998.2024.2444833","article-title":"Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway","volume":"28","author":"Detlie","year":"2025","journal-title":"J. Med. Econ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1007\/s12325-024-02987-7","article-title":"A cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with iron deficiency anemia in China","volume":"41","author":"Zhang","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/13696998.2024.2313932","article-title":"Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England","volume":"27","author":"Iqbal","year":"2024","journal-title":"J. Med. Econ."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:36:50Z","timestamp":1782448610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":83,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124748"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124748","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}